Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Pfizer Gains as UK Nod Boosts Pill’s Prospects Amid Omicron Surge

Published 01/03/2022, 07:22 AM
Updated 01/03/2022, 07:52 AM
© Reuters

© Reuters

By Dhirendra Tripathi

Investing.com – Pfizer (NYSE:PFE) stock traded 0.7% higher in Monday’s premarket as it continued its momentum from U.K.’s approval to the company’s Covid-19 pill, which boosts chances of the oral drug finding wider acceptance amid omicron surge.

The company has earlier said that lab data suggests the antiviral retains its effectiveness against omicron, the fastest-spreading mutant of coronavirus and the reason behind the all-time high daily infections in many countries over last few days, including in the U.S.

The Medicines and Healthcare products Regulatory Agency’s nod came Friday. The pill already has the U.S. Food and Drug Administration’s approval.

The company claims that its pill against the infection has near 90% efficacy in preventing hospitalizations and deaths in high-risk patients.

“We now have a further antiviral medicine for the treatment of Covid-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting, before Covid-19 has progressed to a severe stage,” an MHRA release quoted its Chief Executive June Raine as saying.

The at-home treatment can be prescribed to high-risk patients, 12 years of age and older weighing at least 40 kg (88 lbs), who tested positive for Covid-19 — potentially helping patients avoid severe illness and reducing hospitalizations and deaths from the viral infection. 

The pill is a protease inhibitor, which blocks the activity of a key enzyme that the coronavirus needs in order to replicate. Protease inhibitors are also used to treat HIV, hepatitis C and other viruses.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.